Emergent BioSolutions Inc
EBS
Company Profile
Business description
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN® and other commercial products.
Contact
300 Professional Drive
GaithersburgMD20879
USAT: +1 240 631-3200
E: lindahlr@ebsi.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2024
Employees
1,600
Stocks News & Analysis
stocks
Microsoft earnings: Strength in cloud, guidance mixed
We think investors should be on board when Azure accelerates in the third quarter.
stocks
Chart of the week: Small caps lagging
This week's chart of the week comes from Morningstar's Market Strategist's take on small caps
stocks
An impending merger just raised our fair value for this ASX retail giant
The deal is set to deliver enhanced scale, cost savings and new synergies.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,344.80 | 77.30 | -0.92% |
| CAC 40 | 7,350.37 | 77.99 | -1.05% |
| DAX 40 | 19,077.54 | 179.80 | -0.93% |
| Dow JONES (US) | 41,763.46 | 378.08 | -0.90% |
| FTSE 100 | 8,110.10 | 49.53 | -0.61% |
| HKSE | 20,317.33 | 63.31 | -0.31% |
| NASDAQ | 18,095.15 | 512.78 | -2.76% |
| Nikkei 225 | 39,081.25 | 196.14 | -0.50% |
| NZX 50 Index | 12,579.18 | 59.72 | -0.47% |
| S&P 500 | 5,705.45 | 108.22 | -1.86% |
| S&P/ASX 200 | 8,083.80 | 76.20 | -0.93% |
| SSE Composite Index | 3,279.82 | 13.59 | 0.42% |